YU46753B - RECOMBINANT VIRUS - Google Patents

RECOMBINANT VIRUS

Info

Publication number
YU46753B
YU46753B YU165486A YU165486A YU46753B YU 46753 B YU46753 B YU 46753B YU 165486 A YU165486 A YU 165486A YU 165486 A YU165486 A YU 165486A YU 46753 B YU46753 B YU 46753B
Authority
YU
Yugoslavia
Prior art keywords
virus
recombinant virus
nucleotide sequence
htlv iii
lav
Prior art date
Application number
YU165486A
Other languages
Serbo-Croatian (sh)
Other versions
YU165486A (en
Inventor
S.L. Hu
A.F Purchio
L. Madisen
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of YU165486A publication Critical patent/YU165486A/en
Publication of YU46753B publication Critical patent/YU46753B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

REKOMBINANTNI VIRUS čiji genom sadrži nukleotidnu sekvencu koja kodira epitop LAV/HTLV III, ili njen antigeni deo, koja je pod kontrolom druge sekvence nukleotida koja reguliše ekspresiju gena, tako da se u domaćinu koji je inficiran virusom vrši ekspresija peptida ili proteina srodnog sa epitopom LAV/HTLV III. Prijava sadrži još 9 nezavisnih i 73 zavisna zahteva.A RECOMBINANT VIRUS whose genome contains a nucleotide sequence encoding an LAV / HTLV III epitope, or an antigenic portion thereof, that is controlled by a second nucleotide sequence that regulates gene expression, so that a virus-related peptide or protein is expressed in a virus-infected host / HTLV III. The application contains 9 more independent and 73 dependent requests.

YU165486A 1985-09-25 1986-09-25 RECOMBINANT VIRUS YU46753B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77990985A 1985-09-25 1985-09-25
US84298486A 1986-03-27 1986-03-27
US90521786A 1986-09-09 1986-09-09

Publications (2)

Publication Number Publication Date
YU165486A YU165486A (en) 1989-08-31
YU46753B true YU46753B (en) 1994-05-10

Family

ID=27419757

Family Applications (1)

Application Number Title Priority Date Filing Date
YU165486A YU46753B (en) 1985-09-25 1986-09-25 RECOMBINANT VIRUS

Country Status (22)

Country Link
CN (1) CN1020752C (en)
AT (1) ATA256786A (en)
CH (1) CH676247A5 (en)
DE (1) DE3690508T1 (en)
DK (1) DK455486A (en)
ES (2) ES2002490A6 (en)
FI (1) FI863848A (en)
FR (1) FR2587720A2 (en)
GB (1) GB2181435B (en)
GR (1) GR862412B (en)
HU (1) HU205780B (en)
IE (1) IE59314B1 (en)
IL (1) IL80073A (en)
IT (1) IT1195829B (en)
MY (1) MY103182A (en)
NL (1) NL8602422A (en)
NO (1) NO863803L (en)
NZ (1) NZ217645A (en)
PT (1) PT83434B (en)
SE (4) SE8604007L (en)
WO (1) WO1987002038A1 (en)
YU (1) YU46753B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860915B (en) * 1985-04-08 1986-07-11 Genetic Systems Corp Expression and diagnostic use of gag encoded peptides which are immunologically reactive with antibodies to lav
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
JPS63119428A (en) * 1986-09-19 1988-05-24 オンコーゲン Adoptive immunotherapy for treating aids
IL84154A0 (en) * 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
EP0272858A3 (en) * 1986-12-15 1989-07-12 Repligen Corporation Recombinant hiv envelope proteins produced in insect cells
EP0283327B1 (en) * 1987-01-16 1997-06-25 Institut Pasteur Peptides with the immunological properties of HIV-2
FR2610632B1 (en) * 1987-02-11 1990-12-21 Pasteur Institut CHARACTERISTIC PEPTIDES OF HUMAN IMMUNODEFICIENCY RETROVIRUSES (HIV VIRUSES) THEIR APPLICATIONS IN THE DIAGNOSIS OF INFECTIONS DUE TO CERTAIN OF THESE VIRUSES AND, IF NECESSARY, IN VACCINATION AGAINST AIDS
US5681713A (en) * 1987-05-08 1997-10-28 Smithkline Beecham Corporation Expression of heterologous proteins in Drosophila cells
GB8714802D0 (en) * 1987-06-24 1987-07-29 Proteus Biotech Ltd Synthetic polypeptides
DE10399032I1 (en) * 1987-08-28 2004-01-29 Health Research Inc Recombinant viruses.
FR2620030B1 (en) * 1987-09-07 1990-03-23 Transgene Sa VECTOR FOR THE EXPRESSION OF PROTEINS OF HIV-2 VIRUS, A CAUSAL AGENT FOR AIDS, CELL CULTURE INFECTED OR TRANSFORMED THROUGH THIS VECTOR, PROTEINS OBTAINED, VACCINE AND ANTIBODIES OBTAINED
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
EP0343132B1 (en) * 1988-05-06 1994-08-17 Ferropas Ag Methods and systems for producing HIV antigens
US5043262A (en) * 1988-05-12 1991-08-27 Dana Farber Cancer Institute Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use
AP129A (en) * 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
AU3775789A (en) * 1988-06-10 1990-01-05 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
EP0469089B1 (en) * 1989-04-18 1997-11-19 Applied Biotechnology, Inc. Generation of hybrid genes and proteins by virus-mediated recombination
JP3034025B2 (en) * 1989-06-01 2000-04-17 アプライド・バイオテクノロジー・インコーポレーテツド Self-assembled deficient non-self-replicating virions
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5981276A (en) * 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
FR2676068B1 (en) * 1991-05-02 1994-11-04 Pasteur Institut IMMUNOGENIC RECOMBINANT STRAINS OF B. ANTHRACIS - IMMUNOGENIC COMPOSITIONS CONTAINING THEM.
US5840312A (en) * 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
DK0611397T3 (en) * 1991-11-08 2002-10-07 Upjohn Co Vaccine against cat leukemia virus
DE4405810A1 (en) 1994-02-23 1995-08-24 Behringwerke Ag Peptides derived from a retrovirus from the HIV group and their use
JPH11511112A (en) * 1995-02-10 1999-09-28 ユニバーシティ・オブ・マサチューセッツ Delivery of exogenous compounds
US6013506A (en) * 1995-06-05 2000-01-11 Wardley; Richard C. Feline leukemia virus vaccines
ES2143570T3 (en) * 1995-09-06 2000-05-16 Schablonentechnik Kufstein Ag PROCEDURE FOR THE MANUFACTURE OF A SCREENPRINT TEMPLATE.
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6723558B1 (en) 1996-01-23 2004-04-20 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127839B1 (en) * 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Method for producing a recombinant baculovirus expression vector
US4662514A (en) * 1983-11-01 1987-05-05 Charleswater Products, Inc. Electrically conductive polymeric tubes for static sensitive electronic devices
IL76082A (en) * 1984-08-22 1991-07-18 Us Health Molecular clones of the genome of htlv-iii and a process for the preparation thereof
US9328391B1 (en) * 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
EP0201540B2 (en) * 1984-10-18 2001-10-31 Institut Pasteur Envelope antigens of lymphadenopathy associated virus and their applications
GB8501473D0 (en) * 1985-01-21 1985-02-20 Pasteur Institut Cloned dna sequences
CA1341482C (en) * 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
AU600658B2 (en) * 1984-12-24 1990-08-23 Genentech Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
US4774175A (en) * 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
DK171119B1 (en) * 1985-04-19 1996-06-17 Hoffmann La Roche AIDS virus envelope protein, expression vector carrying the envelope protein, transformants transformed with the expression vector, method of producing the virus envelope protein, method of detecting AIDS antibodies, method of determining AIDS virus, vaccine against AIDS, antibodies against the virus envelope protein and use of it to prepare a vaccine and for testing
FR2586427B1 (en) * 1985-08-20 1988-12-09 Pasteur Institut NUCLEOTIDE AND POLYPEPTIDE SEQUENCES FROM VISNA VIRUS AND THEIR APPLICATION TO DIAGNOSTIC TESTS AND THE PRODUCTION OF IMMUNOGENIC COMPOSITIONS

Also Published As

Publication number Publication date
IE862525L (en) 1987-03-25
ES2002490A6 (en) 1988-08-16
FI863848A0 (en) 1986-09-24
SE9102974D0 (en) 1991-10-14
IL80073A (en) 1995-01-24
NO863803D0 (en) 1986-09-24
NL8602422A (en) 1987-04-16
DK455486D0 (en) 1986-09-24
SE9102975D0 (en) 1991-10-14
GB2181435B (en) 1990-01-10
DE3690508T1 (en) 1988-06-23
GB2181435A (en) 1987-04-23
PT83434B (en) 1988-07-29
WO1987002038A1 (en) 1987-04-09
IT1195829B (en) 1988-10-27
SE8604007D0 (en) 1986-09-23
YU165486A (en) 1989-08-31
CH676247A5 (en) 1990-12-28
FR2587720A2 (en) 1987-03-27
IL80073A0 (en) 1986-12-31
DK455486A (en) 1987-03-26
NO863803L (en) 1987-03-26
CN1020752C (en) 1993-05-19
CN86106632A (en) 1987-05-13
MY103182A (en) 1993-05-29
SE9102976D0 (en) 1991-10-14
FR2587720B2 (en) 1995-02-10
PT83434A (en) 1986-10-01
GR862412B (en) 1987-01-23
IT8667730A0 (en) 1986-09-24
SE9102974L (en) 1993-04-15
FI863848A (en) 1987-03-26
GB8622987D0 (en) 1986-10-29
IE59314B1 (en) 1994-02-09
ATA256786A (en) 1995-05-15
ES2006941A6 (en) 1989-05-16
HUT42133A (en) 1987-06-29
SE9102976L (en) 1993-04-15
SE9102975L (en) 1993-04-15
HU205780B (en) 1992-06-29
SE8604007L (en) 1987-03-26
NZ217645A (en) 1991-11-26

Similar Documents

Publication Publication Date Title
YU46753B (en) RECOMBINANT VIRUS
RU2212899C2 (en) Hcv-immunoreactive polypeptide compositions
DE59504181D1 (en) Peptides derived from a retrovirus from the HIV group and their use
ES2137931T3 (en) GDF-1 AND UOG-1 PROTEINS.
DE69735854D1 (en) POLYPEPTIDES FUSED WITH ALFALFAMOSAICVIRAL OR ILARVIRAL CAPSIDES
ATE328068T1 (en) PAPILLOMAVIRUS VACCINE
DK0596979T3 (en) Plant virus recombinant nucleic acids
NO874159L (en) NEW Lymphokine-Related Peptides.
DE68927025D1 (en) HIV-2 virus variants
DE3650289D1 (en) SPIKE PROTEIN OF THE VIRUS OF INFECTIOUS BRONCHITIS.
KR860004146A (en) Method for preparing oral vaccine
YU46814B (en) FUSION POLYPEPTIDE CONTAINING DUAL REPEATING UNITS OF CIRCUM SPOROZOIT (CS) PROTEIN PLASMODIUM FALCIPARUM
DE3879968D1 (en) MALARIA VACCINE MADE OF COPOLYMER PROTEIN.
DE68915121D1 (en) Contact type image sensor.
BR8700563A (en) PROCESS TO PRODUCE A SELECTED POLYPEPTIDE IN A PROPER HOST INSECT CELL; RECOMBINATOR VECTOR, INFECTED INSECT CELL, PEPTIDE; POLYPEPTIDE MOLECULA; MODIFIED HOST, SURFACE ANTIGEN OF HEPATITIS B VIRUS
DK93886A (en) MOLECULAR CLONING OF THE DELTA ENDOTOXING NET OF BACILLUS THURINGIENSISVAR. israelensis
DK0623172T3 (en) Recombinant Marek's disease virus poxvirus vaccine
NO894573L (en) RECOMBINANT INTERLEUKIN-2 HYBRID PROTEINS.
DE69020848D1 (en) IBV vaccine.
ATE320266T1 (en) INDUCTION OF ANTIGEN-SPECIFIC T CELLS BY INTERFERON
ATE174963T1 (en) CLONING AND EXPRESSION OF A RHOPTRY-ASSOCIATED PROTEIN FROM P. FALCIPARUM
DE3685636D1 (en) LYSOCYME-RELATING PEPTIDES.
FR2739622B1 (en) NEW MEMBRANE PROTEINS FROM HELICOBACTER PYLORI
MY118955A (en) Mutant human hepatitis b viral strain and uses thereof.
DK515286D0 (en) ANTIGENT ACTIVE PROTEINS AND PEPTIDES AND VACCINES AGAINST INFECTIOUS BRONCHITIS VIRUS (IBV)